FN2 Earnings Intelligence
Repligen Corporation earnings overview
Latest Repligen Corporation (RGEN) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Repligen Corporation
The supplied analysis supports a constructive operating picture: record Q3 revenue, strong organic growth, raised 2026 guidance, and continued demand in proteins, chromatography, and analytics. The case still depends on converting the capital-equipment backlog, integrating BioLife, and sustaining Asia Pacific momentum.
Repligen Corporation
Repligen's Q2 update strengthened the growth case: proteins, analytics and Asia Pacific supported organic growth, while improving capital-equipment orders and the BioLife acquisition broaden the opportunity. Execution risks remain in filtration, equipment timing and integration.
Repligen Corporation
Repligen's Q1 analysis supports a constructive outlook: broad franchise growth, strong analytics demand, and China expansion were paired with raised full-year guidance. The key test is whether margin initiatives and capital-equipment demand develop as planned while ATF timing and gene-therapy headwinds persist.
Get the RGEN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.